Stock Events

Stock Events

BeOne Medicines 

$358.17
84
-$4.51-1.24% 18:33 Today

Statistics

Day High
362.67
Day Low
357.58
52W High
385.22
52W Low
253.95
Volume
119,480
Avg. Volume
363,642
Mkt Cap
40.52B
P/E Ratio
67.58
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.12
-0.03
0.07
0.16
Expected EPS
0.14617506948
Actual EPS
N/A

Financials

5.37%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
5.34BRevenue
286.93MNet Income

Analyst Ratings

406.09Average Price Target
The highest estimate is 454.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
91%
Hold
9%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ONC. It's not an investment recommendation.
Microsoft
9
MSFT
NVIDIA
9
NVDA
Meta Platforms
7
META
Broadcom
7
AVGO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap233.78B
Amgen competes in the biotechnology sector focusing on human therapeutics, including oncology, which overlaps with BeiGene's focus on cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a global biopharmaceutical company with a strong portfolio in oncology, competing directly with BeiGene's cancer treatment products.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is known for its extensive range of cancer treatments and immunotherapy products, directly competing with BeiGene's oncology focus.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. operates in the biopharmaceutical field, with significant investments in oncology and inflammatory diseases, making it a competitor to BeiGene.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, with a broad portfolio including oncology, directly competes with BeiGene in the development and marketing of cancer therapies.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is a global biopharmaceutical company with a diverse portfolio that includes oncology, competing with BeiGene in the cancer treatment market.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its pharmaceuticals division, focuses on oncology among other areas, competing with BeiGene in the cancer treatment space.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca PLC has a strong focus on oncology, respiratory, cardiovascular, and metabolic diseases, making it a direct competitor to BeiGene in the oncology market.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is involved in biopharmaceuticals, focusing on oncology and other areas, which puts it in competition with BeiGene.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is a global healthcare leader that competes with BeiGene through its oncology division, developing cancer treatments.

About

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Show more...
CEO
John V. Oyler
Employees
12000
Country
Cayman Islands
ISIN
US07725L1026
WKN
000A1437N

Listings

SA
BR
B1ME34.SA
STU
DE
IJ0.STU
MU
DE
49BA.MU
STU
DE
49BA.STU

0 Comments

Share your thoughts

FAQ

What is BeOne Medicines stock price today?▼
The current price of ONC is $358.17 USD — it has decreased by -1.24% in the past 24 hours. Watch BeOne Medicines stock price performance more closely on the chart.
What is BeOne Medicines stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange BeOne Medicines stocks are traded under the ticker ONC.
Is BeOne Medicines stock price growing?▼
ONC stock has fallen by -2.2% compared to the previous week, the month change is a +11.04% rise, over the last year BeOne Medicines has showed a +12.53% increase.
What is BeOne Medicines market cap?▼
Today BeOne Medicines has the market capitalization of 40.52B
When is the next BeOne Medicines earnings date?▼
BeOne Medicines is going to release the next earnings report on November 05, 2026.
What were BeOne Medicines earnings last quarter?▼
ONC earnings for the last quarter are 0.16 USD per share, whereas the estimation was 0.13 USD resulting in a +23.52% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is BeOne Medicines revenue for the last year?▼
BeOne Medicines revenue for the last year amounts to 5.34B USD.
What is BeOne Medicines net income for the last year?▼
ONC net income for the last year is 286.93M USD.
How many employees does BeOne Medicines have?▼
As of September 04, 2026, the company has 12,000 employees.
In which sector is BeOne Medicines located?▼
BeOne Medicines operates in the Health & Wellness sector.
When did BeOne Medicines complete a stock split?▼
BeOne Medicines has not had any recent stock splits.
Where is BeOne Medicines headquartered?▼
BeOne Medicines is headquartered in BASEL, Cayman Islands.